Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival
- 31 October 1995
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 21 (5), 504-509
- https://doi.org/10.1016/s0748-7983(95)96935-7
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Prospective assessment of the role of five tumour markers in breast cancerCancer Immunology, Immunotherapy, 1991
- Assessment of four monoclonal antibodies as serum markers in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical dataBritish Journal of Cancer, 1990
- Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapyEuropean Journal of Cancer and Clinical Oncology, 1989
- The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breastEuropean Journal of Cancer and Clinical Oncology, 1988
- Metastatic breast cancer with constantly low CEA blood levelsZeitschrift für Krebsforschung und Klinische Onkologie, 1984
- Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancerJAMA, 1983
- Steroid receptors in early breast cancer: Value in prognosisJournal of Steroid Biochemistry, 1981
- Clinical correlation between CEA and breast cancerCancer, 1978
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977